×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PRQR – proqr therapeutics n.v. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PRQR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/9
08:15 am
prqr
ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
Medium
Report
ProQR Therapeutics (PRQR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.
4/8
04:00 pm
prqr
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
Medium
Report
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
4/8
08:51 am
prqr
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board [Yahoo! Finance]
Medium
Report
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board [Yahoo! Finance]
4/8
08:00 am
prqr
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
Medium
Report
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
3/29
07:13 am
prqr
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Low
Report
Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
3/25
08:00 am
prqr
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
Medium
Report
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
3/18
03:18 pm
prqr
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
Low
Report
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
3/12
10:14 am
prqr
ProQR Therapeutics (PRQR) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $9.00 price target on the stock.
Medium
Report
ProQR Therapeutics (PRQR) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $9.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
4/8
04:07 pm
prqr
Form 6-K ProQR Therapeutics N.V. For: Apr 08
Medium
Report
Form 6-K ProQR Therapeutics N.V. For: Apr 08
4/8
08:08 am
prqr
Form 6-K ProQR Therapeutics N.V. For: Apr 08
Low
Report
Form 6-K ProQR Therapeutics N.V. For: Apr 08
3/25
08:02 am
prqr
Form 6-K ProQR Therapeutics N.V. For: Mar 25
Medium
Report
Form 6-K ProQR Therapeutics N.V. For: Mar 25
3/18
04:09 pm
prqr
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Valerio Domenico
Medium
Report
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Valerio Domenico
3/18
04:08 pm
prqr
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Platenburg Gerardus Johannes
Medium
Report
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Platenburg Gerardus Johannes
3/18
04:08 pm
prqr
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Maier Martin Alexander
Medium
Report
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Maier Martin Alexander
3/18
04:06 pm
prqr
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Lawton Alison Frances
Medium
Report
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Lawton Alison Frances
3/18
04:05 pm
prqr
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Hom Dennis
Medium
Report
Form 3 ProQR Therapeutics N.V. For: Mar 18 Filed by: Hom Dennis
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
17.4%
10/16 ProQR prices stock offering; shares down 12% after hours [Seeking Alpha] 15.4%
7/12 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 13.5%
11/20 ProQR Therapeutics NV (NASDAQ: PRQR) had its price target lowered by analysts at Citigroup Inc from $40.00 to $33.00. They now have a "buy" rating on the stock. 13.3%
11/1 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 11.4%
2/6 ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases 10.5%
3/25 ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome 10.4%
10/10 ProQR Therapeutics NV (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc from $34.00 to $40.00. They now have a "buy" rating on the stock. 8.0%
7/29 Form 6-K ProQR Therapeutics N.V. For: Jul 29 6.8%
5/24 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.8%
10/16 ProQR prices stock offering; shares down 12% after hours [Seeking Alpha] 15.4%
7/12 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 13.5%
11/20 ProQR Therapeutics NV (NASDAQ: PRQR) had its price target lowered by analysts at Citigroup Inc from $40.00 to $33.00. They now have a "buy" rating on the stock. 13.3%
11/1 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 11.4%
2/6 ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases 10.5%
3/25 ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome 10.4%
10/10 ProQR Therapeutics NV (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc from $34.00 to $40.00. They now have a "buy" rating on the stock. 8.0%
7/29 Form 6-K ProQR Therapeutics N.V. For: Jul 29 6.8%
5/24 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.8%
TOP News Decliners
3/31
Form 6-K ProQR Therapeutics N.V. For: Mar 31
-21.7%
3/14 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -10.6%
1/30 Form 6-K ProQR Therapeutics N.V. For: Jan 30 -10.3%
10/10 Form 6-K ProQR Therapeutics N.V. For: Oct 10 -9.7%
11/8 Form SC 13G ProQR Therapeutics N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP -9.3%
11/18 ProQR to Present at Upcoming Scientific Conferences -9.3%
8/14 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $10.00 price target on the stock. -8.1%
11/28 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. -7.2%
2/26 Form 6-K ProQR Therapeutics N.V. For: Aug 31 -6.8%
9/30 ProQR to Present at Two Investor Conferences in October -6.6%
3/14 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -10.6%
1/30 Form 6-K ProQR Therapeutics N.V. For: Jan 30 -10.3%
10/10 Form 6-K ProQR Therapeutics N.V. For: Oct 10 -9.7%
11/8 Form SC 13G ProQR Therapeutics N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP -9.3%
11/18 ProQR to Present at Upcoming Scientific Conferences -9.3%
8/14 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $10.00 price target on the stock. -8.1%
11/28 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. -7.2%
2/26 Form 6-K ProQR Therapeutics N.V. For: Aug 31 -6.8%
9/30 ProQR to Present at Two Investor Conferences in October -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: